Page last updated: 2024-11-12

gsk221149a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

GSK221149A: highly selective oxytocin receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	11340891
CHEMBL ID	429736
CHEBI ID	188651
SCHEMBL ID	230301
MeSH ID	M0512721

Synonyms (37)

Synonym
820957-38-8
D08986
retosiban (usan)
gsk-221149a
gsk221149a
CHEMBL429736 ,
gsk-221149
gsk221149
CHEBI:188651
retosiban
(3r,6r)-6-[(2s)-butan-2-yl]-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
bdbm50372608
retosiban [usan:inn]
unii-gie06h28ox
gie06h28ox ,
gsk 221149a
morpholine, 4-((2r)-((3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-6-((1s)-1- methylpropyl)-2,5-dioxo-1-piperazinyl)(2-methyl-4-oxazolyl)acetyl)-
(3r,6r)-6-((2s)-butan-2-yl)-3-(2,3-dihydro-1h-inden-2-yl)-1-((1r)-1-(2-methyl- 1,3-oxazol-4-yl)-2-(morpholin-4-yl)-2-oxoethyl)piperazine-2,5-dione
retosiban [usan]
morpholine, 4-((2r)-2-((3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-6-((1s)-1-methylpropyl)-2,5-dioxo-1-piperazinyl)-2-(2-methyl-4-oxazolyl)acetyl)-
retosiban [inn]
(3r,6r)-6-[(2s)-butan-2-yl]-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2-methyl-1,3-oxazol-4-yl)-2-(morpholin-4-yl)-2-oxoethyl]piperazine-2,5-dione
(3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2-methyl-1,3-oxazol-4-yl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2.5-piperazinedione
PLVGDGRBPMVYPB-FDUHJNRSSA-N
(3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2-methyl-1,3-oxazol-4-yl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
SCHEMBL230301
DTXSID00231559
gsk-221,149-a
gtpl8403
2,5-piperazinedione, 3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-, (3r,6r)-
DB11818
HY-14778
CS-0003555
Q7316883
gsk 221149; gsk 221149a
MS-29186
AKOS040742542

Research Excerpts

Effects

Excerpt	Reference	Relevance
"GSK221149A has been shown to inhibit oxytocin-induced uterine contractions in the anaesthetised rat."	( The discovery of GSK221149A: a potent and selective oxytocin antagonist. Allen, MJ; Borthwick, AD; Brooks, DP; Davies, DE; Edwards, RM; Exall, AM; Hamlett, C; Hickey, DM; Irving, WR; Liddle, J; Mason, AM; McCafferty, GP; Nerozzi, F; Peace, S; Philp, J; Pollard, D; Pullen, MA; Shabbir, SS; Sollis, SL; Westfall, TD; Woollard, PM; Wu, C, 2008)	1.41

Toxicity

Excerpt	Reference	Relevance
" Serious adverse events (SAEs) were primarily captured via CHI."	( Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Trials: ARIOS Follow-up Study. Beach, KJ; Correa, EO; Haque, N; Miller, D; Pimenta, JM; Powell, M; Saade, GR; Scott, R; Snidow, J; Thornton, S, 2023)	0.91
"The current study showed no unexpected adverse outcome or impairment with retosiban based on safety monitoring and neurodevelopment assessments."	( Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Trials: ARIOS Follow-up Study. Beach, KJ; Correa, EO; Haque, N; Miller, D; Pimenta, JM; Powell, M; Saade, GR; Scott, R; Snidow, J; Thornton, S, 2023)	0.91
"· There is a need for an effective and safe treatment for sPTL."	( Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Trials: ARIOS Follow-up Study. Beach, KJ; Correa, EO; Haque, N; Miller, D; Pimenta, JM; Powell, M; Saade, GR; Scott, R; Snidow, J; Thornton, S, 2023)	0.91

Bioavailability

Excerpt	Reference	Relevance
" Epelsiban has low levels of intrinsic clearance against the microsomes of four species, good bioavailability (55%) and comparable potency to atosiban in the rat, but is 100-fold more potent than the latter in vitro and was negative in the genotoxicity screens with a satisfactory oral safety profile in female rats."	( Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. Allen, MJ; Borthwick, AD; Davies, DE; Exall, AM; Hamlett, C; Hickey, DM; Liddle, J; Mason, AM; Nerozzi, F; Peace, S; Pollard, D; Pullen, MA; Smith, IE; Sollis, SL; Stanislaus, DJ; Westfall, TD; Woollard, PM, 2012)	0.38

Dosage Studied

Excerpt	Relevance	Reference
" The study provides the rationale and dosing strategy for further evaluation of the efficacy of retosiban in the treatment of PTL."	( Treatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging study. Baidoo, C; Clayton, L; Fossler, MJ; Montague, TH; Powell, M; Snidow, J; Soergel, D; Stier, B; Thornton, S; Valenzuela, G, 2017)	0.46

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
dipeptide	Any molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0001	1.7536	10.0000	AID317406
Vasopressin V2 receptor	Homo sapiens (human)	Ki	0.9500	0.0004	0.4345	3.9811	AID317415
Oxytocin receptor	Homo sapiens (human)	Ki	0.0019	0.0001	0.0718	0.9780	AID317402; AID317412
Vasopressin V1a receptor	Homo sapiens (human)	Ki	12.0000	0.0002	0.6235	7.0300	AID317413
Vasopressin V1b receptor	Homo sapiens (human)	Ki	10.0000	0.0005	0.1897	1.7820	AID317414
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (88)

Process	via Protein(s)	Taxonomy
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Vasopressin V2 receptor	Homo sapiens (human)
renal water retention	Vasopressin V2 receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Vasopressin V2 receptor	Homo sapiens (human)
activation of adenylate cyclase activity	Vasopressin V2 receptor	Homo sapiens (human)
hemostasis	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Vasopressin V2 receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of gene expression	Vasopressin V2 receptor	Homo sapiens (human)
telencephalon development	Vasopressin V2 receptor	Homo sapiens (human)
response to cytokine	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of intracellular signal transduction	Vasopressin V2 receptor	Homo sapiens (human)
cellular response to hormone stimulus	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Vasopressin V2 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Vasopressin V2 receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Vasopressin V2 receptor	Homo sapiens (human)
suckling behavior	Oxytocin receptor	Homo sapiens (human)
response to amphetamine	Oxytocin receptor	Homo sapiens (human)
muscle contraction	Oxytocin receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Oxytocin receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Oxytocin receptor	Homo sapiens (human)
heart development	Oxytocin receptor	Homo sapiens (human)
lactation	Oxytocin receptor	Homo sapiens (human)
memory	Oxytocin receptor	Homo sapiens (human)
response to xenobiotic stimulus	Oxytocin receptor	Homo sapiens (human)
positive regulation of norepinephrine secretion	Oxytocin receptor	Homo sapiens (human)
telencephalon development	Oxytocin receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Oxytocin receptor	Homo sapiens (human)
response to estradiol	Oxytocin receptor	Homo sapiens (human)
response to progesterone	Oxytocin receptor	Homo sapiens (human)
response to anoxia	Oxytocin receptor	Homo sapiens (human)
response to cytokine	Oxytocin receptor	Homo sapiens (human)
social behavior	Oxytocin receptor	Homo sapiens (human)
response to cocaine	Oxytocin receptor	Homo sapiens (human)
maternal behavior	Oxytocin receptor	Homo sapiens (human)
sperm ejaculation	Oxytocin receptor	Homo sapiens (human)
eating behavior	Oxytocin receptor	Homo sapiens (human)
response to peptide hormone	Oxytocin receptor	Homo sapiens (human)
estrous cycle	Oxytocin receptor	Homo sapiens (human)
positive regulation of blood pressure	Oxytocin receptor	Homo sapiens (human)
digestive tract development	Oxytocin receptor	Homo sapiens (human)
positive regulation of synapse assembly	Oxytocin receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Oxytocin receptor	Homo sapiens (human)
positive regulation of penile erection	Oxytocin receptor	Homo sapiens (human)
ERK1 and ERK2 cascade	Oxytocin receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Oxytocin receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Oxytocin receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Oxytocin receptor	Homo sapiens (human)
female pregnancy	Oxytocin receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Oxytocin receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Oxytocin receptor	Homo sapiens (human)
maternal process involved in parturition	Oxytocin receptor	Homo sapiens (human)
cellular response to hormone stimulus	Oxytocin receptor	Homo sapiens (human)
maternal aggressive behavior	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Vasopressin V1a receptor	Homo sapiens (human)
generation of precursor metabolites and energy	Vasopressin V1a receptor	Homo sapiens (human)
activation of phospholipase C activity	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Vasopressin V1a receptor	Homo sapiens (human)
negative regulation of female receptivity	Vasopressin V1a receptor	Homo sapiens (human)
grooming behavior	Vasopressin V1a receptor	Homo sapiens (human)
blood circulation	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of heart rate	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of glutamate secretion	Vasopressin V1a receptor	Homo sapiens (human)
myotube differentiation	Vasopressin V1a receptor	Homo sapiens (human)
calcium-mediated signaling	Vasopressin V1a receptor	Homo sapiens (human)
telencephalon development	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cell growth	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of prostaglandin biosynthetic process	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cellular pH reduction	Vasopressin V1a receptor	Homo sapiens (human)
social behavior	Vasopressin V1a receptor	Homo sapiens (human)
cellular response to water deprivation	Vasopressin V1a receptor	Homo sapiens (human)
maternal behavior	Vasopressin V1a receptor	Homo sapiens (human)
sperm ejaculation	Vasopressin V1a receptor	Homo sapiens (human)
response to corticosterone	Vasopressin V1a receptor	Homo sapiens (human)
negative regulation of transmission of nerve impulse	Vasopressin V1a receptor	Homo sapiens (human)
transport across blood-brain barrier	Vasopressin V1a receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Vasopressin V1a receptor	Homo sapiens (human)
cellular response to hormone stimulus	Vasopressin V1a receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Vasopressin V1a receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Vasopressin V1b receptor	Homo sapiens (human)
activation of phospholipase C activity	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of phospholipase A2 activity	Vasopressin V1b receptor	Homo sapiens (human)
regulation of cell population proliferation	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Vasopressin V1b receptor	Homo sapiens (human)
symbiont entry into host cell	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of inositol phosphate biosynthetic process	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of arachidonic acid secretion	Vasopressin V1b receptor	Homo sapiens (human)
transport across blood-brain barrier	Vasopressin V1b receptor	Homo sapiens (human)
cellular response to hormone stimulus	Vasopressin V1b receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Vasopressin V1b receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
vasopressin receptor activity	Vasopressin V2 receptor	Homo sapiens (human)
protein binding	Vasopressin V2 receptor	Homo sapiens (human)
peptide binding	Vasopressin V2 receptor	Homo sapiens (human)
peptide hormone binding	Oxytocin receptor	Homo sapiens (human)
peptide binding	Oxytocin receptor	Homo sapiens (human)
vasopressin receptor activity	Oxytocin receptor	Homo sapiens (human)
oxytocin receptor activity	Oxytocin receptor	Homo sapiens (human)
vasopressin receptor activity	Vasopressin V1a receptor	Homo sapiens (human)
protein kinase C binding	Vasopressin V1a receptor	Homo sapiens (human)
protein binding	Vasopressin V1a receptor	Homo sapiens (human)
peptide hormone binding	Vasopressin V1a receptor	Homo sapiens (human)
V1A vasopressin receptor binding	Vasopressin V1a receptor	Homo sapiens (human)
peptide binding	Vasopressin V1a receptor	Homo sapiens (human)
vasopressin receptor activity	Vasopressin V1b receptor	Homo sapiens (human)
protein kinase C binding	Vasopressin V1b receptor	Homo sapiens (human)
peptide binding	Vasopressin V1b receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Process	via Protein(s)	Taxonomy
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
endosome	Vasopressin V2 receptor	Homo sapiens (human)
endoplasmic reticulum	Vasopressin V2 receptor	Homo sapiens (human)
Golgi apparatus	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Vasopressin V2 receptor	Homo sapiens (human)
membrane	Vasopressin V2 receptor	Homo sapiens (human)
endocytic vesicle	Vasopressin V2 receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Vasopressin V2 receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Oxytocin receptor	Homo sapiens (human)
microvillus	Oxytocin receptor	Homo sapiens (human)
adherens junction	Oxytocin receptor	Homo sapiens (human)
apical plasma membrane	Oxytocin receptor	Homo sapiens (human)
plasma membrane	Oxytocin receptor	Homo sapiens (human)
endosome	Vasopressin V1a receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1a receptor	Homo sapiens (human)
endocytic vesicle	Vasopressin V1a receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1a receptor	Homo sapiens (human)
endosome	Vasopressin V1b receptor	Homo sapiens (human)
Golgi apparatus	Vasopressin V1b receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1b receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1b receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay ID	Title	Year	Journal	Article
AID317419	Decrease in oxytocin-induced uterine contractions in iv dosed non-pregnant Sprague-Dawley rat	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317411	Bioavailability in rat at 2 mg/kg, iv or 5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317414	Binding affinity to human vasopressin V1b receptor	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317413	Binding affinity to human vasopressin V1a receptor	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317410	AUC in rat at 5 mg/kg, po in DMSO/PEG400 formulation	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317416	Selectivity for human oxytocin receptor over human vasopressin V1a receptor	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID664081	Intrinsic clearance in cynomolgus monkey liver microsomes	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
AID317412	Binding affinity to recombinant oxytocin receptor	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID513693	Selectivity ratio of Ki for human oxytocin receptor Ki for human vasopressin V2 receptor	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Oral oxytocin antagonists.
AID513682	Displacement of [3H]-oxytocin from oxytocin receptor in human uterus tissue	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Oral oxytocin antagonists.
AID317409	Half life in rat at 2 mg/kg, iv or 5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID513690	Oral bioavailability in rat	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Oral oxytocin antagonists.
AID317415	Binding affinity to human vasopressin V2 receptor	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID664082	Intrinsic clearance in human liver microsomes	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
AID317402	Binding affinity to human oxytocin receptor	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317406	Inhibition of CYP3A4	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317405	Aqueous solubility of the compound	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID664108	Clearance in cynomolgus monkey at 2 mg/kg	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
AID664107	AUC in cynomolgus monkey at 2 mg/kg, po	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
AID317420	AUC in rat at 5 mg/kg, po in HPMC/Tween formulation	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317404	Binding affinity to human serum albumin	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317408	Clearance in rat at 2 mg/kg, iv or 5 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317418	Selectivity for human oxytocin receptor over human vasopressin V2 receptor	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID664109	Oral bioavailability in cynomolgus monkey at 2 mg/kg	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
AID317417	Selectivity for human oxytocin receptor over human vasopressin V1b receptor	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID317407	Selectivity for human oxytocin receptor over vasopressin V1a receptor	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	The discovery of GSK221149A: a potent and selective oxytocin antagonist.
AID513692	Selectivity ratio of Ki for human oxytocin receptor Ki for human vasopressin V1a receptor	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Oral oxytocin antagonists.
AID1346469	Human OT receptor (Vasopressin and oxytocin receptors)	2007	American journal of physiology. Regulatory, integrative and comparative physiology, Jul, Volume: 293, Issue:1	Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (15.38)	29.6817
2010's	8 (61.54)	24.3611
2020's	3 (23.08)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (30.77%)	5.53%
Reviews	1 (7.69%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (61.54%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.11	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	2.11	1	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
opc 21268 OPC 21268: structure given in first source; vasopressin V1 receptor antagonist	2.05	1	0
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	4.41	1	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	2.75	3	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
atosiban [no description available]	2.04	1	0	oligopeptide
l 372662 L 372662: structure in first source	2.05	1	0
l 371257 L 371257: structure given in first source	2.05	1	0
l 368899 [no description available]	2.05	1	0
epelsiban epelsiban: structure in first source	2.53	2	0	dipeptide
pituitrin Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).	2.03	1	0
obe001 OBE001: an oxytocin receptor antagonist	2.05	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	0	2.03	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	7.77	7	2
Preterm Birth [description not available]	0	7.53	5	2
Premature Birth CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).	1	9.53	5	2
Labor, Premature [description not available]	0	6.21	3	2

chemdatabank.com